title: Treatment of advanced Hodgkin's disease with high dose melphalan and autologous bone marrow transplantation.
abstract: Twenty patients with Hodgkin's disease which had relapsed at least once after chemotherapy, were treated with melphalan 140-220 mg/m2 i.v. followed by reinfusion of non-cryopreserved autologous bone marrow. Four patients (20%) remain alive and disease-free 28, 45, 52, and 96 months after treatment respectively. There were no treatment-related deaths. This appears to be the only reported series of patients treated with a single agent in this situation. The results are comparable to those achieved by multi-agent regimens with autologous or allogeneic bone marrow transplantation.
authors.affiliation: Department of Medicine, Tom Baker Cancer Centre and Foothills Hospital, Calgary, Canada.
authors.forename: J A
authors.initials: JA
authors.lastname: Russell
authors.forename: P J
authors.initials: PJ
authors.lastname: Selby
authors.forename: B A
authors.initials: BA
authors.lastname: Ruether
authors.forename: E K
authors.initials: EK
authors.lastname: Mbidde
authors.forename: S
authors.initials: S
authors.lastname: Ashley
authors.forename: G
authors.initials: G
authors.lastname: Zulian
authors.forename: J
authors.initials: J
authors.lastname: Berry
authors.forename: B
authors.initials: B
authors.lastname: Houwen
authors.forename: A R
authors.initials: AR
authors.lastname: Jones
authors.forename: M C
authors.initials: MC
authors.lastname: Poon
mesh_terms: D000328:Adult; D016026:Bone Marrow Transplantation; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D008875:Middle Aged; D014182:Transplantation, Autologous
chemical_list: D008558:Melphalan